Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Patterson

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.
British Journal of Haematology|November 16, 2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopRoger G Owen, Robert A Kyle, Marvin J Stone, et al.
The New England Journal of Medicine|April 9, 2015
Ibrutinib in previously treated Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood|February 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemiaHao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu, et al.
Frontiers in Immunology|February 5, 2025
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findingsSteven P Treon, Camille N Kotton, David J Park, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.
British Journal of Haematology|November 16, 2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopRoger G Owen, Robert A Kyle, Marvin J Stone, et al.
The New England Journal of Medicine|April 9, 2015
Ibrutinib in previously treated Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood|February 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemiaHao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu, et al.
Frontiers in Immunology|February 5, 2025
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findingsSteven P Treon, Camille N Kotton, David J Park, et al.
Pageof 11